Cuprina Holdings
Singapore-based MedTech company that specialises in the development of products to treat chronic wounds. MEDIFLY, a bio-dressing made of live, medical-grade maggots, is used by private and public hospitals in Singapore and Hong Kong to disinfect and debride chronic wounds, known as Maggot Debridement Therapy (MDT). Our product is clinically-proven to reduce amputation rates and eliminate infections in chronic wounds, especially diabetic foot ulcers and pressure ulcers. We are ISO13485 certified and our MEDIFLY products are HSA registered as class C medical devices.
Cuprina develops bio-dressing using ‘maggot debridement therapy'
The biotech’s product, MEDIFLY, is an innovative approach to help eliminate necrotic tissues in wounds.
Cuprina develops bio-dressing using ‘maggot debridement therapy'
The biotech’s product, MEDIFLY, is an innovative approach to help eliminate necrotic tissues in wounds.
Most Read
1. Malaysia’s health expenditure to grow by 8.3% CAGR until 2028 2. IHH Healthcare’s proton therapy centre emphasises precise target treatment for cancer 3. How Kuwait’s Vision 2035 development plan is driving healthcare expenditure 4. Icon Singapore and SAM Holdings partner in driving proton therapy treatment 5. India’s Omega Hospitals adopts robotic system for targeted radiation therapyResource Center
Read Here
Advertise
Sign Up
Event News
Event News
Beyond borders: Deloitte's Kavita Rekhraj explores trends, tech, and collaborations shaping healthcare in SEA
![Beyond borders: Deloitte's Kavita Rekhraj explores trends, tech, and collaborations shaping healthcare in SEA]()
Co-Written / Partner
Her perspectives underscore the importance of agile, technology-driven approaches and cross-sector collaborations to address the dynamic healthcare needs of the region.
Her perspectives underscore the importance of agile, technology-driven approaches and cross-sector collaborations to address the dynamic healthcare needs of the region.
